Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Coronary Heart Disease Incidence: Depression & Inflammation Risk
Coronary Heart Disease Incidence: Depression & Inflammation Risk
Status: Enrolling
Updated:  2/4/2016
Columbia University
mi
from
New York, NY
Coronary Heart Disease Incidence: Depression & Inflammation Risk
Coronary Heart Disease Incidence: Depression & Inflammation Risk
Status: Enrolling
Updated: 2/4/2016
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Washington DC VA Medical Center, Washington, DC
mi
from
Washington,
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated:  2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
mi
from
Perry Point, MD
Reducing Internalized Stigma in People With Serious Mental Illness
Reducing Internalized Stigma In People With Serious Mental Illness
Status: Enrolling
Updated: 2/5/2016
Perry Point VA Medical Center VA Maryland Health Care System, Perry Point, MD
mi
from
Perry Point, MD
Click here to add this to my saved trials
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  2/8/2016
Rush University
mi
from
Chicago, IL
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 2/8/2016
Rush University
mi
from
Chicago, IL
Click here to add this to my saved trials
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  2/8/2016
University of Kansas
mi
from
Wichita, KA
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 2/8/2016
University of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  2/8/2016
Temple University
mi
from
Philadelphia, PA
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 2/8/2016
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  2/8/2016
Brown University-Butler Hospital
mi
from
Providence, RI
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 2/8/2016
Brown University-Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated:  2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
mi
from
New Haven, CT
Duloxetine for the Treatment of Postpartum Depression
Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder
Status: Enrolling
Updated: 2/9/2016
Perinatal & Postpartum Research Program 142 Temple ST Suite 301
mi
from
New Haven, CT
Click here to add this to my saved trials
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated:  2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated: 2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients
Status: Enrolling
Updated:  2/9/2016
University Hospital
mi
from
Indianapolis, IN
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients
Status: Enrolling
Updated: 2/9/2016
University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
Motivational Antidepressant Therapy for Hispanics
Status: Enrolling
Updated:  2/11/2016
New York State Psychiatric Institute, 1051 Riverside Drive
mi
from
New York, NY
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
Motivational Antidepressant Therapy for Hispanics
Status: Enrolling
Updated: 2/11/2016
New York State Psychiatric Institute, 1051 Riverside Drive
mi
from
New York, NY
Click here to add this to my saved trials
Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls
Depression and Insulin Resistance in Adolescents
Status: Enrolling
Updated:  2/11/2016
Colorado State University
mi
from
Fort Collins, CO
Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls
Depression and Insulin Resistance in Adolescents
Status: Enrolling
Updated: 2/11/2016
Colorado State University
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US009
mi
from
Jacksonville, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US009
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US015
mi
from
Tucson, AZ
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US015
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US019
mi
from
Glendale, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US019
mi
from
Glendale, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US016
mi
from
Oakland, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US016
mi
from
Oakland, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US014
mi
from
San Diego, CA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US014
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US011
mi
from
Denver, CO
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US011
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US018
mi
from
Hallandale Beach, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US018
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US005
mi
from
Orlando, FL
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US005
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US006
mi
from
Gaithersburg, MD
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US006
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US012
mi
from
Weymouth, MA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US012
mi
from
Weymouth, MA
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US003
mi
from
Jamaica, NY
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US003
mi
from
Jamaica, NY
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US001
mi
from
Dayton, OH
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US001
mi
from
Dayton, OH
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US007
mi
from
Portland, OR
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US007
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US004
mi
from
Memphis, TN
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US004
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated:  2/16/2016
US002
mi
from
Seattle, WA
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
Status: Enrolling
Updated: 2/16/2016
US002
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Kansas
mi
from
Wichita, KA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Marlton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Marlton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Global Medical Institutes, Llc
mi
from
Princeton, NJ
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Global Medical Institutes, Llc
mi
from
Princeton, NJ
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Michael R Liebowitz MD
mi
from
New York, NY
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Michael R Liebowitz MD
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Phildadelphia, PA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Phildadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
CRI Lifetree
mi
from
Salt Lake City, UT
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
CRI Lifetree
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
University of Alabama Office of Psychiatric Clinical Research
mi
from
Birmingham, AL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
University of Alabama Office of Psychiatric Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
mi
from
Encino, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
mi
from
Encino, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pacific Institute for Medical Research Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmacology Research Institute
mi
from
Newport Beach, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Sarkis Clinical Trials
mi
from
Gainesville, FL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Chicago Research Center, Inc
mi
from
Chicago, IL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Chicago Research Center, Inc
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Evanston Premier Healthcare Research, LLC
mi
from
Northbrook, IL
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Evanston Premier Healthcare Research, LLC
mi
from
Northbrook, IL
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Pharmasite Research
mi
from
Baltimore, MD
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Pharmasite Research
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Bostin Clinical Trials, Inc.
mi
from
Roslindale, MA
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Bostin Clinical Trials, Inc.
mi
from
Roslindale, MA
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Clinilabs Inc.
mi
from
New York, NY
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Clinilabs Inc.
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated:  2/18/2016
Finger Lake Clinical Research
mi
from
Rochester, NY
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Status: Enrolling
Updated: 2/18/2016
Finger Lake Clinical Research
mi
from
Rochester, NY
Click here to add this to my saved trials